Azora Therapeutics, Inc. (AZR) Stock Ticker
Market factors today
Unlock the full AZR picture
About Azora Therapeutics, Inc.
Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.
AZR stock facts
| Ticker symbol | AZR |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical - Pharmaceuticals |
| Market cap | $12.8M |
| CEO | Cary J. Claiborne |
| Employees | 6 |
| Headquarters | Glen Allen, VA, US |
| IPO date | 2018-07-27 |
| Website | azoratherapeutics.com |
What you can see for AZR on Tickr
Live AZR price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the AZR report.
Rankings
FAQ
What is the ticker symbol for Azora Therapeutics, Inc.?
The ticker symbol for Azora Therapeutics, Inc. is AZR, listed on the NASDAQ.
What is AZR?
Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.